These results suggest that L-VGCCs may be a therapeutic target for inhibiting early DR and topical administration of GLP-1R agonists could provide a noninvasive and effective approach in the treatment of the retinopathy independently of their hypoglycemic action. Here, GLP1R is linked to retinal disorder.